Perrigo Company plc Company Profile (NYSE:PRGO)

About Perrigo Company plc (PRGO)

Perrigo Company plc logoPerrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. Its businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia. In February 2014, the Company announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Related Products
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: PRGO
  • CUSIP: 71429010
Key Metrics:
  • Previous Close: $69.09
  • 50 Day Moving Average: $75.23
  • 200 Day Moving Average: $83.18
  • 52-Week Range: $66.86 - $133.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.09
  • P/E Growth: 5.79
  • Market Cap: $9.91B
  • Outstanding Shares: 143,374,000
  • Beta: 0.73
  • Net Margins: -26.62%
  • Return on Equity: 10.68%
  • Return on Assets: 5.39%
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 1.71%
  • Quick Ratio: 1.13%

Analyst Ratings

Consensus Ratings for Perrigo Company plc (NYSE:PRGO) (?)
Ratings Breakdown: 1 Sell Rating, 13 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $96.43 (39.57% upside)

Analysts' Ratings History for Perrigo Company plc (NYSE:PRGO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/18/2017Canaccord GenuitySet Price TargetBuy$86.00MediumView Rating Details
3/14/2017Deutsche Bank AGLower Price TargetBuy$93.00 -> $87.00LowView Rating Details
3/8/2017B. RileyReiterated RatingNeutral$67.00LowView Rating Details
2/28/2017Jefferies Group LLCSet Price TargetHold$70.00 -> $71.00N/AView Rating Details
2/28/2017GuggenheimReiterated RatingBuy$125.00N/AView Rating Details
2/28/2017Royal Bank of CanadaLower Price Target$68.00N/AView Rating Details
2/6/2017Barclays PLCLower Price TargetOverweight$110.00 -> $100.00N/AView Rating Details
1/30/2017Goldman Sachs Group IncReiterated RatingSellN/AView Rating Details
11/10/2016JPMorgan Chase & Co.Set Price TargetHold$95.00N/AView Rating Details
11/11/2016Bank of America CorpUpgradeUnderperform -> NeutralN/AView Rating Details
9/27/2016ArgusReiterated RatingHoldN/AView Rating Details
8/10/2016Leerink SwannSet Price TargetHold$96.00 -> $81.00N/AView Rating Details
8/11/2016Northland SecuritiesDowngradeOutperform -> Market Perform$123.00 -> $94.00N/AView Rating Details
6/17/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
6/15/2016Raymond James Financial, Inc.Reiterated RatingHoldN/AView Rating Details
5/14/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
4/25/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
4/25/2016Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
2/22/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
6/23/2015BMO Capital MarketsInitiated CoverageOutperform$246.00N/AView Rating Details
(Data available from 3/29/2015 forward)


Earnings History for Perrigo Company plc (NYSE:PRGO)
Earnings by Quarter for Perrigo Company plc (NYSE:PRGO)
Earnings History by Quarter for Perrigo Company plc (NYSE:PRGO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316$1.58$1.65$1.28 billion$1.40 billionViewN/AView Earnings Details
8/10/2016Q216$1.98$1.93$1.43 billion$1.48 billionViewListenView Earnings Details
5/12/2016Q116$1.75$1.75$1.35 billion$1.34 billionViewListenView Earnings Details
2/18/2016Q415$1.93$1.80$1.46 billion$1.42 billionViewListenView Earnings Details
10/22/2015Q3$1.73$1.76$1.42 billion$1.34 billionViewListenView Earnings Details
8/5/2015Q2$1.96$2.18$1.52 million$1.53 millionViewN/AView Earnings Details
4/21/2015Q315$1.78$1.85$1.10 billion$1.05 billionViewN/AView Earnings Details
2/5/2015Q215$1.79$1.82$1.09 billion$1.07 billionViewN/AView Earnings Details
11/6/2014Q115$1.44$1.40$997.90 million$951.50 millionViewN/AView Earnings Details
8/14/2014Q414$1.55$1.74$1.09 billion$1.14 billionViewN/AView Earnings Details
5/7/2014Q314$1.51$1.31$1.07 billion$1,000.00 millionViewN/AView Earnings Details
2/6/2014Q214$1.59$1.87$996.68 million$979.00 millionViewN/AView Earnings Details
10/31/2013Q114$1.40$1.52$900.10 million$933.00 millionViewN/AView Earnings Details
8/15/2013Q4 2013$1.56$1.57$999.08 million$967.20 millionViewN/AView Earnings Details
5/7/2013Q3 2013$1.44$1.42$935.44 million$919.83 millionViewN/AView Earnings Details
2/1/2013Q2 2013$1.31$1.36$881.84 million$882.96 millionViewN/AView Earnings Details
11/7/2012Q113$1.24$1.27$825.83 million$769.80 millionViewN/AView Earnings Details
8/16/2012$1.27$1.28ViewN/AView Earnings Details
5/8/2012$1.22$1.41ViewN/AView Earnings Details
2/7/2012$1.15$1.20ViewN/AView Earnings Details
10/27/2011$1.06$1.10ViewN/AView Earnings Details
8/16/2011$0.97$1.02ViewN/AView Earnings Details
5/3/2011$0.97$1.07ViewN/AView Earnings Details
2/1/2011$0.95$1.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Perrigo Company plc (NYSE:PRGO)
Current Year EPS Consensus Estimate: $7.11 EPS
Next Year EPS Consensus Estimate: $5.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$2.27$2.27$2.27
Q2 20161$2.47$2.47$2.47
Q3 20161$2.25$2.25$2.25
Q4 20161$2.42$2.42$2.42
(Data provided by Zacks Investment Research)


Current Dividend Information for Perrigo Company plc (NYSE:PRGO)
Most Recent Dividend:3/21/2017
Annual Dividend:$0.58
Dividend Yield:0.84%
Dividend Growth:17.20% (3 Year Average)
Payout Ratio:-5.53% (Trailing 12 Months of Earnings)
8.16% (Based on This Year's Estimates)
10.98% (Based on Next Year's Estimates)
Track Record:14 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Perrigo Company plc (NYSE:PRGO)

Dividend History by Quarter for Perrigo Company plc (NYSE:PRGO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Perrigo Company plc (NYSE:PRGO)
Insider Ownership Percentage: 4.47%
Institutional Ownership Percentage: 69.65%
Insider Trades by Quarter for Perrigo Company plc (NYSE:PRGO)
Institutional Ownership by Quarter for Perrigo Company plc (NYSE:PRGO)
Insider Trades by Quarter for Perrigo Company plc (NYSE:PRGO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/25/2016Judy L BrownEVPSell2,097$89.44$187,555.68View SEC Filing  
11/21/2016Geoffrey M ParkerDirectorBuy2,500$88.75$221,875.00View SEC Filing  
10/24/2016Judy L BrownEVPSell2,092$90.42$189,158.64View SEC Filing  
9/26/2016Judy L BrownCFOSell2,096$96.76$202,808.96View SEC Filing  
9/26/2016Thomas FarringtonEVPSell1,110$96.76$107,403.60View SEC Filing  
9/9/2016Gary K Kunkle JrDirectorSell5,814$89.95$522,969.30View SEC Filing  
9/8/2016Herman Morris JrDirectorSell1,073$90.96$97,600.08View SEC Filing  
8/26/2016Judy L BrownEVPSell2,095$88.28$184,946.60View SEC Filing  
4/13/2016Judy L BrownCFOSell2,776$126.22$350,386.72View SEC Filing  
3/18/2016Michael J JandernoaDirectorSell761$128.29$97,628.69View SEC Filing  
3/2/2016Sharon KochanEVPSell1,490$125.28$186,667.20View SEC Filing  
2/24/2016Judy L BrownCFOSell2,776$123.73$343,474.48View SEC Filing  
1/6/2016Judy L. BrownCFOSell27,737$142.41$3,950,026.17View SEC Filing  
12/28/2015Joseph C. PapaChairmanSell10,183$147.07$1,497,613.81View SEC Filing  
8/25/2015John T. HendricksonEVPSell1,737$181.37$315,039.69View SEC Filing  
8/25/2015Todd W. KingmaVPSell1,715$181.37$311,049.55View SEC Filing  
8/24/2015John T. HendricksonEVPSell4,468$177.68$793,874.24View SEC Filing  
4/29/2015Todd W KingmaVPSell1,700$190.27$323,459.00View SEC Filing  
4/14/2015John T HendricksonEVPSell8,800$200.27$1,762,376.00View SEC Filing  
4/13/2015Todd W KingmaVPSell1,300$198.44$257,972.00View SEC Filing  
3/13/2015Jatin ShahSVPSell2,000$165.50$331,000.00View SEC Filing  
10/1/2014Judy L BrownCFOSell3,515$150.72$529,780.80View SEC Filing  
9/3/2014Sharon KochanEVPSell1,116$150.00$167,400.00View SEC Filing  
9/3/2014Todd W KingmaVPSell2,250$149.65$336,712.50View SEC Filing  
9/2/2014Judy L BrownCFOSell3,515$149.32$524,859.80View SEC Filing  
9/2/2014Thomas FarringtonVPSell1,741$150.36$261,776.76View SEC Filing  
8/27/2014Michael Robert StewartVPSell4,519$148.78$672,336.82View SEC Filing  
8/26/2014Jeffrey NeedhamVPSell10,205$148.54$1,515,850.70View SEC Filing  
8/26/2014Judy L BrownCFOSell4,827$148.87$718,595.49View SEC Filing  
8/25/2014John T HendricksonEVPSell2,533$148.44$375,998.52View SEC Filing  
5/15/2014Ran GottfriedDirectorSell1,000$131.25$131,250.00View SEC Filing  
3/24/2014Joseph PapaChairmanSell10,000$157.72$1,577,200.00View SEC Filing  
1/16/2014Joseph PapaChairmanSell5,000$157.59$787,950.00View SEC Filing  
12/12/2013Gary CohenDirectorSell4,632$152.52$706,472.64View SEC Filing  
12/12/2013Joseph PapaChairmanSell15,000$150.12$2,251,800.00View SEC Filing  
12/9/2013Michael JandernoaDirectorSell128,620$155.30$19,974,686.00View SEC Filing  
11/25/2013Louis YuVPSell2,292$155.51$356,428.92View SEC Filing  
11/21/2013Judy BrownCFOSell9,988$154.74$1,545,543.12View SEC Filing  
11/20/2013John HendricksonEVPSell8,400$152.80$1,283,520.00View SEC Filing  
11/4/2013Ran GottfriedDirectorSell2,275$143.36$326,144.00View SEC Filing  
9/24/2013Joseph PapaChairmanSell15,000$124.60$1,869,000.00View SEC Filing  
9/18/2013John HendricksonEVPSell2,161$125.00$270,125.00View SEC Filing  
9/11/2013Michael Robert StewartVPSell5,063$123.37$624,622.31View SEC Filing  
9/9/2013Louis YuVPSell1,852$124.11$229,851.72View SEC Filing  
9/6/2013John T HendricksonEVPSell1,000$123.46$123,460.00View SEC Filing  
9/4/2013John T HendricksonEVPSell2,000$123.92$247,840.00View SEC Filing  
9/3/2013Judy BrownCFOSell2,500$122.07$305,175.00View SEC Filing  
8/30/2013Jeffrey NeedhamVPSell6,585$120.47$793,294.95View SEC Filing  
8/29/2013Sharon KochanVPSell3,467$120.98$419,437.66View SEC Filing  
8/27/2013Joseph PapaChairmanSell15,000$117.64$1,764,600.00View SEC Filing  
8/26/2013John HendricksonEVPSell2,099$119.15$250,095.85View SEC Filing  
8/26/2013Judy BrownCFOSell3,424$119.28$408,414.72View SEC Filing  
8/20/2013John HendricksonEVPSell1,676$118.56$198,706.56View SEC Filing  
8/20/2013Judy BrownCFOSell2,804$118.58$332,498.32View SEC Filing  
8/20/2013Thomas FarringtonVPSell1,658$119.86$198,727.88View SEC Filing  
8/16/2013Todd KingmaVPSell1,250$120.00$150,000.00View SEC Filing  
7/19/2013Todd W KingmaVPSell1,250$129.37$161,712.50View SEC Filing  
7/11/2013Joseph C PapaChairmanSell10,000$128.54$1,285,400.00View SEC Filing  
7/9/2013John T HendricksonEVPSell2,161$125.00$270,125.00View SEC Filing  
6/14/2013Joseph C PapaChairmanSell10,000$118.39$1,183,900.00View SEC Filing  
6/14/2013Todd W KingmaVPSell1,250$118.00$147,500.00View SEC Filing  
6/4/2013Judy L BrownCFOSell2,500$116.38$290,950.00View SEC Filing  
5/14/2013Sharon KochanVPSell2,647$119.64$316,687.08View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Perrigo Company plc (NYSE:PRGO)
Latest Headlines for Perrigo Company plc (NYSE:PRGO)
DateHeadline logoPERRIGO CO PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhib - March 29 at 8:05 PM logoPerrigo (PRGO) Completes Divestiture of Tysabri Royalty Stream - March 28 at 7:07 PM logoPerrigo Completes Divestiture Of Tysabri® Royalty Stream For Up To $2.85 Billion - March 27 at 6:47 PM logoHow These Healthcare Stocks are Faring? -- BioScrip, Community Health Systems, Perrigo, and Health Insurance Innovations - March 24 at 8:17 AM logoStarboard Value's Jeff Smith Is Top Activist for Naming New Board Members - March 23 at 8:36 AM logoPerrigo Company plc -- Moody's: Perrigo's delayed 10-K filing is credit negative - March 20 at 5:24 PM logoMoody's: Perrigo Filing Delay a "Credit Negative" - March 20 at 5:24 PM logoPerrigo Company plc (PRGO) PT Lowered to $87.00 at Deutsche Bank AG - March 20 at 11:34 AM logoPerrigo Company plc (PRGO) Price Target Raised to $100.00 at Canaccord Genuity - March 19 at 7:01 PM logoPERRIGO CO PLC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tr - March 17 at 7:29 PM logoPerrigo (PRGO) Offers Update on 10-K Filing - - March 17 at 1:07 AM logoPerrigo Provides Update On 2016 Form 10-K Filing - March 16 at 8:06 PM logoPERRIGO CO PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat - March 16 at 8:06 PM logoResearch Analysts’ Weekly Ratings Changes for Perrigo Company plc (PRGO) - March 16 at 2:06 PM logoStock market holds its ground as Fed rate decision looms - March 13 at 7:02 PM logoPerrigo Company plc (PRGO) Price Target Cut to $68.00 - March 12 at 4:30 PM logoRPI Finance Trust -- Moody's confirms RPI Finance Trust at Baa2; negative outlook - March 9 at 7:11 PM logoPerrigo Launches First to Market OTC Equivalent of Rogaine - March 9 at 7:11 PM logoPerrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine® Foam - March 8 at 8:56 AM logoPerrigo Provides 2016 Form 10-K Update - March 7 at 7:13 PM logo4:22 pm Perrigo issues statement on its 2016 Form 10-K, says in the process of identifying certain deferred tax assets and other related effects at Omega Pharma - March 7 at 7:13 PM logoPerrigo Joins Firms With Generic Drugs Under U.S. Glare - March 3 at 7:21 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Perrigo Company plc - March 2 at 12:35 AM logoPerrigo Announces FDA Final Approval For The Generic Version Of Axiron® Topical Solution, 30 mg/1.5 mL - March 2 at 12:35 AM logoPawar Law Group Announces Investigation of Securities Claims Against Perrigo Company plc - PRGO - March 2 at 12:35 AM logoPerrigo Expects FY16 Adj. EPS In Range Of $7.10 - $7.25 - Quick Facts - Nasdaq - March 1 at 5:19 AM logoPerrigo sells Tysabri royalty stream, delays annual report - Reuters - March 1 at 5:19 AM logoFaber Report: Papa don't preach - February 28 at 3:48 PM logoRPI Finance Trust -- Moody's reviews RPI Finance Trust for downgrade - February 28 at 3:48 PM logoEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Perrigo Company plc – PRGO - February 28 at 3:48 PM logoPerrigo Stock Slump Highlights Dubious Milestone - February 28 at 3:48 PM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Perrigo Company plc (PRGO) - February 28 at 3:48 PM logoTwo biotechs taking it on the chin - February 28 at 3:48 PM logoStocks retreat as investors await big Trump speech - February 28 at 3:48 PM logo7 Takeaways From Perrigo's Preliminary Q4 Results - February 28 at 2:51 PM logoPerrigo 2016 top-line up 5%; non-GAAP EPS down 6%; shares off 10% after hours - February 27 at 5:33 PM logoPerrigo Company (PRGO) Slides on Earnings Anticipation - February 27 at 4:11 PM logoPerrigo Announces Leadership Changes - February 27 at 4:11 PM logoPerrigo Signs Agreement To Divest Tysabri® Royalty Stream For Up To $2.85 Billion - February 27 at 4:11 PM logoPerrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance - February 27 at 4:11 PM logoQ4 2016 Perrigo Company PLC Earnings Release - After Market Close - February 27 at 9:44 AM logoPerrigo Company plc Announces Quarterly Dividend - PR Newswire (press release) - February 23 at 12:28 AM logoCoverage initiated on Perrigo by Canaccord Genuity - February 22 at 7:27 PM logoIsraeli supermarket chain Shufersal Q4 profit up - February 22 at 9:22 AM logoPerrigo Company plc Announces Quarterly Dividend - February 21 at 5:34 PM logoPerrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution - February 17 at 8:08 PM logo8:44 am Perrigo receives FDA approval for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL - February 17 at 8:08 PM logoPerrigo To Release Fourth Quarter And Calendar Year 2016 Results On February 27, 2017 - February 14 at 11:47 PM


Frequently Asked Questions for Perrigo Company plc (NYSE:PRGO)

What is Perrigo Company plc's stock symbol?

Perrigo Company plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

How often does Perrigo Company plc pay dividends? What is the dividend yield for Perrigo Company plc?

Perrigo Company plc declared a quarterly dividend on Tuesday, February 21st. Stockholders of record on Friday, March 3rd will be paid a dividend of $0.16 per share on Tuesday, March 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend is Wednesday, March 1st. This is a positive change from Perrigo Company plc's previous quarterly dividend of $0.15.

How were Perrigo Company plc's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) released its quarterly earnings data on Wednesday, August, 10th. The company reported $1.93 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.98 by $0.05. The firm had revenue of $1.48 billion for the quarter, compared to analysts' expectations of $1.43 billion. Perrigo Company plc had a negative net margin of 26.62% and a positive return on equity of 10.68%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.18 EPS.

When will Perrigo Company plc make its next earnings announcement?

Perrigo Company plc is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.

What guidance has Perrigo Company plc issued on next quarter's earnings?

Perrigo Company plc issued an update on its FY16 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $6.85-7.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.95.

Where is Perrigo Company plc's stock going? Where will Perrigo Company plc's stock price be in 2017?

18 brokers have issued 12 month target prices for Perrigo Company plc's stock. Their predictions range from $67.00 to $160.00. On average, they expect Perrigo Company plc's stock price to reach $96.43 in the next twelve months.

What are analysts saying about Perrigo Company plc stock?

Here are some recent quotes from research analysts about Perrigo Company plc stock:

  • 1. Deutsche Bank AG analysts commented, "We updated our model to reflect PRGO's divestiture of the Tysabri royalty stream to Royalty Pharma, which the company expects to complete this month, and preliminary assumptions for de-leveraging with the proceeds. The net effect of these changes was EPS dilution of ~15-20% over 2017-21 and a reduction in our DCF-derived PT to $87 (from $93), as our prior model reflected more value for the Tysabri royalty stream (~$3bn) relative to the upfront payment of $2.2bn. We have not factored in the potential sales-based milestone payments of $650mn, which could add ~$4/share to the theoretical DCF value if they hit. We continue to view PRGO as a unique asset with good value creation potential over the longer term, and are maintaining our Buy rating. Solid execution in the coming quarters will be critical for the stock, in our view." (3/14/2017)
  • 2. Jefferies Group LLC analysts commented, "Unaudited Q4 results were ahead of forecast. But the real story is FY17 guidance and it disappointed even after sharp cuts to Street models just 4 weeks ago. For the first time we can recall both rev & EPS will decline ' not a good story line for an OTC-focused company. Tysabri's sale helps de-lever PRGO but at the same time shrinks the EPS base by ~$2.20. Mgt continues to make moves to enhance shareholder value ' but it may take quite some time to do so." (2/28/2017)
  • 3. Royal Bank of Canada analysts commented, "While we expected a challenging 2017 guide, it was worse than we anticipated and came with an unexpected CFO departure. The strategic review around whether to sell Rx/generics will linger, limiting visibility but the conundrum is that we do not see upside in either scenario. We remain on the sidelines with target down to $68. Several additional thoughts after speaking with management this evening." (2/28/2017)
  • 4. According to Zacks Investment Research, "Perrigo has a presence in the OTC market and sells generic and specialty pharma drugs as well. We are positive on the company’s focus on acquisition-driven growth. The Mar 2015 Omega Pharma acquisition has expanded product offerings in the European OTC market. Going forward, we could see more of such merger & acquisition activities at the company. Moreover, the company’s restructuring plans to boost shareholder value look encouraging. However, the company had provided a dull outlook for both 2016 earnings and revenues, which is concerning. The cut in the earnings guidance reflects softness in pricing in the Rx segment due to industry and competitive pressures. The company expects this softness to continue impacting its fundamentals through 2016. The reduction was also due to a weaker performance expected within the BCH segment over the next three quarters as well as low expectations for consolidated new product launches." (7/25/2016)

Who owns Perrigo Company plc stock?

Perrigo Company plc's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.27%), Franklin Resources Inc. (2.34%), Aberdeen Asset Management PLC UK (1.28%), Migdal Insurance & Financial Holdings Ltd. (0.99%), Ruane Cunniff & Goldfarb Inc. (0.92%) and Camber Capital Management LLC (0.84%). Company insiders that own Perrigo Company plc stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, John T Hendrickson, Joseph C Papa, Judy L Brown, Michael J Jandernoa, Sharon Kochan, Thomas Farrington and Todd W Kingma.

Who sold Perrigo Company plc stock? Who is selling Perrigo Company plc stock?

Perrigo Company plc's stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd., Aberdeen Asset Management PLC UK, Menora Mivtachim Holdings LTD., Baird Financial Group Inc., Ruane Cunniff & Goldfarb Inc., Putnam Investments LLC, Silvercrest Asset Management Group LLC and Public Sector Pension Investment Board. Company insiders that have sold Perrigo Company plc stock in the last year include Gary K Kunkle Jr, Herman Morris Jr, Judy L Brown and Thomas Farrington.

Who bought Perrigo Company plc stock? Who is buying Perrigo Company plc stock?

Perrigo Company plc's stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, State Street Corp, FMR LLC, Credit Agricole S A, Highbridge Capital Management LLC, Allianz Asset Management AG and Marshall Wace LLP.

How do I buy Perrigo Company plc stock?

Shares of Perrigo Company plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Perrigo Company plc stock cost?

One share of Perrigo Company plc stock can currently be purchased for approximately $69.09.

Perrigo Company plc (PRGO) Chart for Wednesday, March, 29, 2017

This page was last updated on 3/29/2017 by Staff